Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01082965 · ClinicalTrials.gov registry record · NA
Acute Effects Of Donepezil On Brain Perfusion And Memory In Subjects With Cognitive Impairment And Mild Alzheimer's Disease
A NA study, sponsored by Pfizer.
- Terminated
- Registry status
- NA
- Development phase
- 18
- Enrollment target
NCT01082965 is a NA study that was terminated before completion, run by Pfizer. The registered enrollment target is 18 participants.
The verdict
NCT01082965, a NA study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- NA
- Development phase
- 18 participants
- Enrollment target
Study Summary
The study hypothesizes that donepezil will have a positive impact on brain blood flow deficits in subjects with memory deficits and/or mild dementia and that improvements in brain blood flow will be accompanied by improvements in memory.
Interventions
- DRUG Placebo
- DRUG Donepezil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2010-07 |
| Est. Completion | 2012-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01082965
The ClinicalTrials.gov registry entry for NCT01082965 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01082965 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01082965 about?
NCT01082965 is a clinical study titled "Acute Effects Of Donepezil On Brain Perfusion And Memory In Subjects With Cognitive Impairment And Mild Alzheimer's Disease". The study hypothesizes that donepezil will have a positive impact on brain blood flow deficits in subjects with memory deficits and/or mild dementia and that improvements in brain blood flow will be accompanied by improvements in memory.
What is the current status of trial NCT01082965?
This trial is currently terminated. It is a NA study. The enrollment target is 18 participants. The study started on 2010-07. Estimated completion is 2012-07.
What interventions are being tested in trial NCT01082965?
The interventions under investigation include: Placebo (DRUG), Donepezil (DRUG).
Who is sponsoring clinical trial NCT01082965?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.